New Injectable Agents for the Treatment of Type 2 Diabetes Part 1 – Injectable Insulins

Christa George, Ah Young Byun, Amanda Howard-Thompson

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The United States Food and Drug Administration has recently approved several new insulin products and new formulations of existing insulin products. These new products may provide advantages over older products, such as a lower risk of nocturnal hypoglycemia and ease of dosing; however, they are costly. The first of 2 articles in a series, this review will describe the potential advantages and disadvantages of these new insulin products.

Original languageEnglish (US)
Pages (from-to)752-754
Number of pages3
JournalAmerican Journal of Medicine
Volume131
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Insulins
Type 2 Diabetes Mellitus
Insulin
Injections
United States Food and Drug Administration
Hypoglycemia
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

New Injectable Agents for the Treatment of Type 2 Diabetes Part 1 – Injectable Insulins. / George, Christa; Byun, Ah Young; Howard-Thompson, Amanda.

In: American Journal of Medicine, Vol. 131, No. 7, 01.07.2018, p. 752-754.

Research output: Contribution to journalReview article

George, Christa ; Byun, Ah Young ; Howard-Thompson, Amanda. / New Injectable Agents for the Treatment of Type 2 Diabetes Part 1 – Injectable Insulins. In: American Journal of Medicine. 2018 ; Vol. 131, No. 7. pp. 752-754.
@article{f679cc2b18a7410fb6e05370dade6b97,
title = "New Injectable Agents for the Treatment of Type 2 Diabetes Part 1 – Injectable Insulins",
abstract = "The United States Food and Drug Administration has recently approved several new insulin products and new formulations of existing insulin products. These new products may provide advantages over older products, such as a lower risk of nocturnal hypoglycemia and ease of dosing; however, they are costly. The first of 2 articles in a series, this review will describe the potential advantages and disadvantages of these new insulin products.",
author = "Christa George and Byun, {Ah Young} and Amanda Howard-Thompson",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.amjmed.2018.01.049",
language = "English (US)",
volume = "131",
pages = "752--754",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - New Injectable Agents for the Treatment of Type 2 Diabetes Part 1 – Injectable Insulins

AU - George, Christa

AU - Byun, Ah Young

AU - Howard-Thompson, Amanda

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The United States Food and Drug Administration has recently approved several new insulin products and new formulations of existing insulin products. These new products may provide advantages over older products, such as a lower risk of nocturnal hypoglycemia and ease of dosing; however, they are costly. The first of 2 articles in a series, this review will describe the potential advantages and disadvantages of these new insulin products.

AB - The United States Food and Drug Administration has recently approved several new insulin products and new formulations of existing insulin products. These new products may provide advantages over older products, such as a lower risk of nocturnal hypoglycemia and ease of dosing; however, they are costly. The first of 2 articles in a series, this review will describe the potential advantages and disadvantages of these new insulin products.

UR - http://www.scopus.com/inward/record.url?scp=85044508769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044508769&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2018.01.049

DO - 10.1016/j.amjmed.2018.01.049

M3 - Review article

VL - 131

SP - 752

EP - 754

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 7

ER -